earnings
confidence high
sentiment positive
materiality 0.85
ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+
ADMA BIOLOGICS, INC.
2025-Q3 EPS reported
$0.40
revenue$371,010,000
- GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).
- Revenue guidance raised: FY25 to ≥$510M (from >$500M); FY26 to ≥$630M (from >$625M).
- Adj EBITDA guidance: FY25 reaffirmed at $235M; FY26 raised to >$355M (from >$340M).
- FDA lot release of first yield-enhanced batches; gross margin expansion expected from Q4 2025.
- Record ASCENIV demand; real-world data shows >50% infection reduction (2.1→0.9/year).